
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Avapritinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : CStone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
CStone gets NMPA Approval for AYVAKIT CDx Kit Developed with Genetron
Details : Ayvakit (avapritinib) is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants, indicated for gastrointestinal stromal tumors.
Product Name : Ayvakit
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Avapritinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : CStone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Avapritinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : CStone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
CStone and Genetron Launch Avapritinib CDx Clinical Trial in China
Details : Ayvakit (avapritinib) is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants, indicated for gastrointestinal stromal tumors.
Product Name : Ayvakit
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Avapritinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : CStone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!